Nov 29, 2022 / 06:50PM GMT
Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division - MD & Fundamental Research Analyst
Hi, everyone. Thanks for joining our conference. We're very pleased to be hosting Alnylam today. My name is Liisa Bayko. I'm one of the analysts here at Evercore ISI, and this is HealthConX 2022 in case you're in the wrong place. And this is the Alnylam team. And Alnylam had -- I think it's such an interesting company and had great success so far with their RNAi platform and more to come and some great data that's really kind of, I think, woke people up and we're excited to dig in. So maybe we can start off by just some quick introductions. Jeff and Eric, do you want to briefly introduce yourself and then we'll get started.
Jeffrey V. Poulton - Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Sure. Maybe I'll go first. I'm Jeff Poulton. I've been with Alnylam for about 3.5 years now. I'm the Chief Financial Officer.
Eric Green - Alnylam Pharmaceuticals, Inc. - VP and General Manager of TTR Program
Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers